Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR8942992

—

c20ca281-ffdb-5cf4-ada7-0cb5bbfed483

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TNFA_SIGNALING_VIA_NFKB+0.520
  • INTERFERON_ALPHA_RESPONSE+0.500
  • INTERFERON_GAMMA_RESPONSE+0.460
  • CHOLESTEROL_HOMEOSTASIS+0.450
  • IL6_JAK_STAT3_SIGNALING+0.430
  • ANGIOGENESIS+0.420
  • E2F_TARGETS+0.410
  • INFLAMMATORY_RESPONSE+0.410
  • MYC_TARGETS_V1+0.410
  • MTORC1_SIGNALING+0.390

Top 10 suppressed

  • WNT_BETA_CATENIN_SIGNALING-0.200
  • PROTEIN_SECRETION-0.150
  • HEME_METABOLISM-0.100
  • HEDGEHOG_SIGNALING-0.090
  • UV_RESPONSE_DN-0.090
  • SPERMATOGENESIS-0.010
  • DNA_REPAIR+0.010
  • BILE_ACID_METABOLISM+0.020
  • APICAL_JUNCTION+0.070
  • IL2_STAT5_SIGNALING+0.080

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
15063882F-6377-4976-BB48-7275D46C44E6
brain-umap@2
——0.911
2MDT-AP-0428
medullo-epn-umap@date-based
MedMedulloblastoma0.905
3AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE
brain-umap@2
——0.904
4MDT-AP-1106
medullo-epn-umap@date-based
MedMedulloblastoma0.903
5MDT-AP-2822
medullo-epn-umap@date-based
MedMedulloblastoma0.900
6MDT-AP-2001
medullo-epn-umap@date-based
MedMedulloblastoma0.891
7MDT-AP-2036
medullo-epn-umap@date-based
MedMedulloblastoma0.883
8TCGA-G2-A2ES-01A-11R-A180-07
bladder-landscape@3
——0.882
9TCGA-ZF-A9RD-01A-11R-A42T-07
bladder-landscape@3
——0.882
10TCGA-A2-A0SV-01A-11R-A084-07
breast-umap@18
—C0.879

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 44 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TNFA_SIGNALING_VIA_NFKB0.520Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.500Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.460Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.450Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.430Inavolisib— uncovered
ANGIOGENESIS0.420Remibrutinib— uncovered
E2F_TARGETS0.410Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.410Idelalisib— uncovered
MYC_TARGETS_V10.410Inavolisib— uncovered
MTORC1_SIGNALING0.390Inavolisib— uncovered
HYPOXIA0.380Idelalisib— uncovered
UV_RESPONSE_UP0.360Idelalisib— uncovered
ALLOGRAFT_REJECTION0.350Idelalisib— uncovered
G2M_CHECKPOINT0.350Inavolisib— uncovered
APOPTOSIS0.340Idelalisib— uncovered
P53_PATHWAY0.330Idelalisib— uncovered
ANDROGEN_RESPONSE0.310Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.300Remibrutinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.290Inavolisib— uncovered
COMPLEMENT0.280Inavolisib— uncovered